Yun Kong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yun Kong has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
Yongheng Rong
State Key Laboratory of Microbial Technology, Shandong University, Qingdao 266000, China
9 shared publications- Min Chen
State Key Laboratory of Microbial Technology, Shandong University, Qingdao 266000, China
7 shared publications Peng George Wang
School of Medicine, Southern University of Science and Technology, Shenzhen 518055, China
5 shared publicationsWeian Mao
National Glycoengineering Research Center, Shandong Key Laboratory of Carbohydrate Chemistry and Glycobiology, State Key Laboratory of Microbial Technology, Shandong University, Qingdao 266237, China
5 shared publicationsMin Chen
National Glycoengineering Research Center, Shandong Key Laboratory of Carbohydrate Chemistry and Glycobiology, State Key Laboratory of Microbial Technology, Shandong University, Qingdao 266237, China
4 shared publicationsShengjun Wang
School of Health and Life Sciences, University of Health and Rehabilitation Sciences, Qingdao 266071, China
4 shared publications
Latest Publications
- 3 November 2026
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 62 (86) , 22035-22038
Multi-enzyme cascade reactions synthesize diverse structurally defined glycoside conjugates
A coupled biocatalytic system bypasses nucleotide sugar intermediates, enabling economical synthesis of structurally defined glycoconjugates from monosaccharide donors.
- 3 November 2026
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 62 (86) , 22035-22038
Multi-enzyme cascade reactions synthesize diverse structurally defined glycoside conjugates
A coupled biocatalytic system bypasses nucleotide sugar intermediates, enabling economical synthesis of structurally defined glycoconjugates from monosaccharide donors.
- 28 February 2026
- Published by American Chemical Society (ACS) in Biomacromolecules
- Vol. 27 (4) , 2699-2710
Glycosylated Human Heavy Chain Ferritin Nanoparticles Enhance Liver-Targeted Drug Delivery
As a ubiquitous iron-storage protein, human heavy chain ferritin (FTH) is widely used in drug delivery. Recent advances in FTH engineering highlight the therapeutic and translational potential of glycosylation. We herein report the biosynthesis of various glycosylated FTHs (Glc-FTH, Glcn-FTH, and Gal-Glc-FTH) in Escherichia coli via enzymatic methods. Their self-assembly and thermal stability are unaffected by glycosylation, while the acid sensitivity is significantly enhanced, enabling depolymerization in a milder and more controllable manner. Gal-Glc-FTH exhibits exceptional advantages (low cytotoxicity, low immunogenicity, minimal apoptosis-inducing ability, prolonged half-life, and strong hepatic targeting), which collectively enhance its applications in hepatic targeted drug delivery. Although Glcn-FTH also significantly enhances hepatic targeting, its induction of high-titer antibodies indicates that it is more suitable for development as a vaccine carrier. Our findings emphasize the critical role of glycans in FTH properties, providing novel strategies and insights for cancer-targeted drug delivery systems.
- 28 February 2026
- Published by American Chemical Society (ACS) in Biomacromolecules
- Vol. 27 (4) , 2699-2710
Glycosylated Human Heavy Chain Ferritin Nanoparticles Enhance Liver-Targeted Drug Delivery
As a ubiquitous iron-storage protein, human heavy chain ferritin (FTH) is widely used in drug delivery. Recent advances in FTH engineering highlight the therapeutic and translational potential of glycosylation. We herein report the biosynthesis of various glycosylated FTHs (Glc-FTH, Glcn-FTH, and Gal-Glc-FTH) in Escherichia coli via enzymatic methods. Their self-assembly and thermal stability are unaffected by glycosylation, while the acid sensitivity is significantly enhanced, enabling depolymerization in a milder and more controllable manner. Gal-Glc-FTH exhibits exceptional advantages (low cytotoxicity, low immunogenicity, minimal apoptosis-inducing ability, prolonged half-life, and strong hepatic targeting), which collectively enhance its applications in hepatic targeted drug delivery. Although Glcn-FTH also significantly enhances hepatic targeting, its induction of high-titer antibodies indicates that it is more suitable for development as a vaccine carrier. Our findings emphasize the critical role of glycans in FTH properties, providing novel strategies and insights for cancer-targeted drug delivery systems.
- 12 August 2025
- Published by Elsevier in Bioorganic Chemistry
- Vol. 164, 108870
An insect β1–3-galactosyltransferase enables efficient synthesis of multi-sites T antigen glycoconjugates
- 12 August 2025
- Published by Elsevier in Bioorganic Chemistry
- Vol. 164, 108870
An insect β1–3-galactosyltransferase enables efficient synthesis of multi-sites T antigen glycoconjugates
- 21 March 2025
- Published by Elsevier in Protein Expression and Purification
- Vol. 231, 106712
High soluble expression and characterization of human GalNAc transferase T2 and T11 in Escherichia coli
- 21 March 2025
- Published by Elsevier in Protein Expression and Purification
- Vol. 231, 106712
High soluble expression and characterization of human GalNAc transferase T2 and T11 in Escherichia coli
- 17 February 2025
- Published by Elsevier in Bioorganic Chemistry
- Vol. 157, 108290
Characterization and application in recombinant N-GlcNAc-protein production of a novel endo-β-N-acetylglucosaminidase from Listeria booriae
- 17 February 2025
- Published by Elsevier in Bioorganic Chemistry
- Vol. 157, 108290
Characterization and application in recombinant N-GlcNAc-protein production of a novel endo-β-N-acetylglucosaminidase from Listeria booriae
- 16 January 2023
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 59 (13) , 1797-1800
O -GalNAc glycosylation affects the immunogenicity of the receptor-binding domain (RBD) of SARS-CoV-2 spike protein
Herein, O -GalNAc glycosylated RBD (Tn-RBD) was synthesized as antigen via in vitro glycosylation reactions. The inhibition ability against hACE2 binding of antibodies induced with Tn-RBD was 30–40% increased.
- 16 January 2023
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 59 (13) , 1797-1800
O -GalNAc glycosylation affects the immunogenicity of the receptor-binding domain (RBD) of SARS-CoV-2 spike protein
Herein, O -GalNAc glycosylated RBD (Tn-RBD) was synthesized as antigen via in vitro glycosylation reactions. The inhibition ability against hACE2 binding of antibodies induced with Tn-RBD was 30–40% increased.
- 12 September 2022
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 8 (10) , 2198-2206
Chemoenzymatic Synthesis of SARS-CoV-2 Homogeneous O-Linked Glycopeptides for Exploring Their Inhibition Functions
Harnessing highly conserved peptides derived from the receptor binding domain (RBD) of spike (S) protein to construct peptide-based inhibitors is one of the most effective strategies to fight against the ever-mutating coronavirus SARS-CoV-2. But how the O-glycosylation affects their inhibition abilities has not been intensively explored. Herein, an intrinsic O-glycosylated peptide P320-334 derived from RBD was screened and homogeneous O-linked glycopeptides containing Tn (GalNAcα1-O-Ser/Thr), T (Galβ1-3GalNAcα1-O-Ser/Thr), sialyl-Tn (sTn, Siaα2-6GalNAcα1-O-Ser/Thr), and sialyl-T (sT, Siaα2-3Galβ1-3GalNAcα1-O-Ser/Thr) structures were first synthesized via chemoenzymatic strategies. Compared with the unglycosylated peptide, the binding of sT-P320-334 to hACE2 was enhanced to 133% and the inhibition capacity against RBD-hACE2 binding of sTn- and sT-P320-334 was significantly increased up to 150-410%. Thus, our results suggest the sialic acid residue on the terminal of short O-glycan structures might strengthen the inhibition capacities of these peptide-based inhibitors, which might provide novel optimization directions for the inhibitor design.
- 12 September 2022
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 8 (10) , 2198-2206
Chemoenzymatic Synthesis of SARS-CoV-2 Homogeneous O-Linked Glycopeptides for Exploring Their Inhibition Functions
Harnessing highly conserved peptides derived from the receptor binding domain (RBD) of spike (S) protein to construct peptide-based inhibitors is one of the most effective strategies to fight against the ever-mutating coronavirus SARS-CoV-2. But how the O-glycosylation affects their inhibition abilities has not been intensively explored. Herein, an intrinsic O-glycosylated peptide P320-334 derived from RBD was screened and homogeneous O-linked glycopeptides containing Tn (GalNAcα1-O-Ser/Thr), T (Galβ1-3GalNAcα1-O-Ser/Thr), sialyl-Tn (sTn, Siaα2-6GalNAcα1-O-Ser/Thr), and sialyl-T (sT, Siaα2-3Galβ1-3GalNAcα1-O-Ser/Thr) structures were first synthesized via chemoenzymatic strategies. Compared with the unglycosylated peptide, the binding of sT-P320-334 to hACE2 was enhanced to 133% and the inhibition capacity against RBD-hACE2 binding of sTn- and sT-P320-334 was significantly increased up to 150-410%. Thus, our results suggest the sialic acid residue on the terminal of short O-glycan structures might strengthen the inhibition capacities of these peptide-based inhibitors, which might provide novel optimization directions for the inhibitor design.
- 1 September 2020
- Published by Elsevier in Enzyme and Microbial Technology
- Vol. 139, 109568
Substrate specificity of the galactokinase from the human gut symbiont Akkermansia muciniphila ATCC BAA-835
- 1 September 2020
- Published by Elsevier in Enzyme and Microbial Technology
- Vol. 139, 109568
Substrate specificity of the galactokinase from the human gut symbiont Akkermansia muciniphila ATCC BAA-835
- Open Access
- 13 January 2020
- Published by Springer Nature in Microbial Cell Factories
- Vol. 19 (1) , 1-11
Homogeneous production and characterization of recombinant N-GlcNAc-protein in Pichia pastoris
Background: Therapeutic glycoproteins have occupied an extremely important position in the market of biopharmaceuticals. N-Glycosylation of protein drugs facilitates them to maintain optimal conformations and affect their structural stabilities, serum half-lives and biological efficiencies. Thus homogeneous N-glycoproteins with defined N-glycans are essential in their application in clinic therapeutics. However, there still remain several obstacles to acquire homogeneous N-glycans, such as the high production costs induced by the universal utilization of mammalian cell expression systems, the non-humanized N-glycan structures and the N-glycosylation microheterogeneities between batches. Results: In this study, we constructed a Pichia pastoris (Komagataella phaffii) expression system producing truncated N-GlcNAc-modified recombinant proteins through introducing an ENGase isoform (Endo-T) which possesses powerful hydrolytic activities towards high-mannose type N-glycans. The results showed that the location of Endo-T in different subcellular fractions, such as Endoplasmic reticulum (ER), Golgi or cell membrane, affected their hydrolytic efficiencies. When the Endo-T was expressed in Golgi, the secreted IgG1-Fc region was efficiently produced with almost completely truncated N-glycans and the N-GlcNAc modification on the glycosite Asn297 was confirmed via Mass Spectrometry. Conclusion: This strategy develops a simple glycoengineered yeast expression system to produce N-GlcNAc modified proteins, which could be further extended to different N-glycan structures. This system would provide a prospective platform for mass production of increasing novel glycoprotein drugs.
- 13 January 2020
- Published by Springer Nature in Microbial Cell Factories
- Vol. 19 (1) , 1-11
Open AccessHomogeneous production and characterization of recombinant N-GlcNAc-protein in Pichia pastoris
Background: Therapeutic glycoproteins have occupied an extremely important position in the market of biopharmaceuticals. N-Glycosylation of protein drugs facilitates them to maintain optimal conformations and affect their structural stabilities, serum half-lives and biological efficiencies. Thus homogeneous N-glycoproteins with defined N-glycans are essential in their application in clinic therapeutics. However, there still remain several obstacles to acquire homogeneous N-glycans, such as the high production costs induced by the universal utilization of mammalian cell expression systems, the non-humanized N-glycan structures and the N-glycosylation microheterogeneities between batches. Results: In this study, we constructed a Pichia pastoris (Komagataella phaffii) expression system producing truncated N-GlcNAc-modified recombinant proteins through introducing an ENGase isoform (Endo-T) which possesses powerful hydrolytic activities towards high-mannose type N-glycans. The results showed that the location of Endo-T in different subcellular fractions, such as Endoplasmic reticulum (ER), Golgi or cell membrane, affected their hydrolytic efficiencies. When the Endo-T was expressed in Golgi, the secreted IgG1-Fc region was efficiently produced with almost completely truncated N-glycans and the N-GlcNAc modification on the glycosite Asn297 was confirmed via Mass Spectrometry. Conclusion: This strategy develops a simple glycoengineered yeast expression system to produce N-GlcNAc modified proteins, which could be further extended to different N-glycan structures. This system would provide a prospective platform for mass production of increasing novel glycoprotein drugs.
- 15 May 2019
- Published by Springer Nature in Science China Life Sciences
- Vol. 62 (7) , 985-987
A new strategy for high-throughput identification of human gut microbiota containing specific monosaccharide
- 15 May 2019
- Published by Springer Nature in Science China Life Sciences
- Vol. 62 (7) , 985-987
A new strategy for high-throughput identification of human gut microbiota containing specific monosaccharide